INTRODUCTION
============

C-reactive protein (CRP) is a sensitive and nonspecific systemic marker of inflammation ([@B1]). Increased CRP levels are associated with mortality, coronary heart disease, and stroke ([@B2], [@B3]). Serum CRP levels are substantially influenced by genetic factors, with a heritability of 35% to 40% ([@B4]). White blood cell count (WBC) is also a marker of systemic inflammation and higher WBC count has been associated with cardiovascular disease incidence and mortality ([@B5], [@B6]). WBC count is also moderately influenced by heritable factors, with heritability estimates ranging from 14% to 40% across the WBC subtypes ([@B7]).

Apolipoprotein E (apoE = protein, *APOE* = gene) has a central role in the metabolism of cholesterol and triglycerides ([@B8], [@B9], [@B10]). *APOE* gene has three common alleles (*E2*, *E3*, and *E4*) arising from two single nucleotide polymorphisms (rs429358 and rs7412) in exon 4 that give six possible genotypes (*E2E2, E2E3, E2E4, E3E3, E3E4*, and *E4E4*) ([@B11]). *APOE* genotypes have been associated with ischemic cerebrovascular disease ([@B12]) and coronary heart disease ([@B13]). Differences among *APOE* genotypes in the risk of cardiovascular disease have traditionally been explained by lipid metabolism. In previous our study of the same data set, *APOE* genotypes was associated with carotid atherosclerosis and this association was partly mediated through blood lipid ([@B14]). However, *APOE* genotype may also affect the risk of cardiovascular disease through anti-inflammatory and antioxidant properties of apoE protein ([@B15], [@B16]).

Since Manttari and colleagues first described the association of *APOE E4* allele with low CRP levels in 2001, many studies have investigated relationships between *APOE* genotype and CRP levels. Most studies have reported that *E4* allele is associated with low levels of CRP ([@B17], [@B18], [@B19], [@B20], [@B21], [@B22], [@B23], [@B24], [@B25], [@B26]). However, there is little research on the relationship between other markers of inflammation and *APOE* genotype. In addition, most studies were carried out in Caucasians, and few studies have been carried out in Asians. Therefore, we evaluated the association of the *APOE* genotype with serum CRP levels and WBC in two large population-based studies in South Korea.

MATERIALS AND METHODS
=====================

Subjects
--------

The Dong-gu Study and Namwon Study are ongoing prospective studies designed to investigate the prevalence, incidence, and risk factors for chronic disease in urban and rural populations, respectively. Details of the study subjects and measurements have been published previously ([@B27]).

In the Dong-gu Study, 9,260 subjects aged 50 yr and older were recruited in the baseline survey between April 2007 and June 2010 in the Dong-gu district of Gwangju Metropolitan City in South Korea. Of these, 101 subjects were excluded because of missing data on *APOE* genotype, CRP, WBC, blood lipids and medical history and smoking. Subjects with WBC counts of less than 2,000 cells/μL or more than 12,000 cells/μL and/or CRP ≥ 10 mg/L were excluded because of a high probability of acute inflammation and other medical disorders, which left 8,893 (3,525 men and 5,368 women) for analysis.

In the Namwon Study, 10,667 participants (4,201 men and 6,466 women) were recruited in the baseline survey between January 2004 and February 2007 in Namwon city of Jeollabuk-do province in South Korea. Of these, 225 subjects were excluded because of missing data on *APOE* genotype, CRP, WBC, blood lipids and medical history and smoking. Subjects with WBC counts of less than 2,000 cells/μL or more than 12,000 cells/μL and/or CRP ≥ 10 mg/L were excluded, which left 10,032 (3,909 men and 6,123 women) for analysis.

*APOE* genotyping
-----------------

Genomic DNA was extracted from peripheral blood with an AccuPrep Genomic DNA Extraction Kit (Bioneer, Seoul, Korea) or a QIAamp DNA Mini Kit (Qiagen Inc., Chatsworth, CA, USA) according to the manufacturer\'s protocol. *APOE* genotypes were determined as described by Hixson and Vernier, with slight modifications ([@B28]). Our *APOE* genotyping method has been reported previously ([@B29]). The genotyping method was validated by direct sequencing (ABI PRISM 3100 Genetic Analyzer, Applied Biosystems) of 96 subjects with 100% concordance.

Other clinical variables
------------------------

Demographic characteristics, lifestyle and medical history were obtained by standardized questionnaires. Smoking status was classified into non-smoker and current smoker. Height was measured to the nearest 0.1 cm, and weight to the nearest 0.1 kg. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared.

Diabetes was defined by a fasting plasma glucose ≥ 126 mg/dL or use of antidiabetic medication. Blood pressure was measured in the right upper arm using a mercury sphygmomanometer (Baumanometer; WA Baum Co, Inc, Copiague, NY, USA) with an appropriately sized cuff after subjects rested at least 5 min while seated. Three consecutive measurements of systolic and diastolic blood pressures were performed at 1-min intervals, and the average was used in the analysis. Hypertension was defined by systolic blood pressure ≥ 140 or diastolic blood pressure ≥ 90 mmHg, or use of antihypertensive medication.

Blood samples were drawn from an antecubital vein in the morning after a 12-hr overnight fast. Serum was separated within 30 min and stored at -70℃ until analyzed. Serum total cholesterol, high-density lipoprotein cholesterol (HDL), triglycerides, and fasting blood glucose levels were measured using enzymatic methods. All samples were analyzed using an automatic analyzer (model 7600 chemical analyzer; Hitachi Ltd, Tokyo, Japan). CRP level was determined by means of particle-enhanced immunonephelometry using BN II nephelometer (Dade Behring, Marburg, Germany). The lower detection limit for CRP was 0.2 mg/L. White blood cell (WBC) count was determined using a cell counter (Micro 60, ABX, Montpellier, France).

Statistical analysis
--------------------

Data are presented as mean ± standard deviation (SD) or percentage for categorical variables. Because the distribution of triglycerides and CRP levels was skewed, triglycerides and CRP values were logarithmically transformed, and geometric means with 95% confidence intervals are presented. The *APOE* genotypes were categorized into *E2E2*, *E2E3*, *E2E4*, *E3E3*, *E3E4*, and *E4E4*. The *APOE* genotype was also categorized into three groups for analytical purposes: *APOE E2* (*E2E2* and *E2E3*), *APOE E3* (*E3E3*), and *APOE* E4 (*E3E4* and *E4E4*). Subjects with the *E2E4* genotype were excluded because of the opposing biological effects of the *E2* and *E4* alleles. Multivariable linear regression analysis was performed to evaluate the association between *APOE* genotypes and CRP levels and white blood cell count after adjusting for age, sex, BMI, smoking, diabetes and hypertension, total cholesterol, HDL cholesterol, and log-transformed triglycerides. The Bonferroni method was used to correct multiple comparisons. Hardy-Weinberg equilibrium was tested by use of a chi-square goodness of fit test. Statistical analyses were performed using the SPSS version 21.0 (SPSS, Inc., an IBM Company, Chicago, IL, USA).

Ethics statement
----------------

This study was conducted in accordance with the Declaration of Helsinki guidelines. The study protocol was approved by the institutional review board of Chonnam National University Hospital (Dong-gu Study, IRB No. I-2008-05-056; Namwon Study, IRB No. I-2007-07-062), and informed consent was obtained from each subject.

RESULTS
=======

The baseline characteristics of the study subjects are presented in [Table 1](#T1){ref-type="table"}. The mean age was 65.1±8.2 yr in the Dong-gu Study, and 61.6±8.0 yr in the Namwon Study. The *APOE* genotype frequencies were consistent with Hardy-Weinberg equilibrium (*P*=0.86 for the Dong-gu Study, *P*=0.91 for the Namwon Study) and not significantly different. The frequency of *APOE* genotypes for *E2E2*, *E2E3*, *E2E4*, *E3E3*, *E3E4*, and *E4E4* was 0.4, 10.7, 1.3, 71.0, 15.6, and 1.0%, respectively in the Dong-gu Study and 0.4, 10.2, 1.1, 72.6, 14.9, and 0.9%, respectively in the Namwon Study.

The associations of *APOE* genotypes and allele with CRP are shown in [Table 2](#T2){ref-type="table"}. There was significant difference in CRP across the *APOE* genotypes and alleles in both studies in all Models. Carriers of *E3E4* or *E4E4* genotype had significantly lower CRP levels compared with carriers of *APOE E3E3* genotype group in both studies (0.51 mg/L vs. 0.67 mg/L; 0.37 mg/L vs. 0.67 mg/L, respectively, for the Dong-gu Study and 0.48 mg/L vs. 0.67 mg/L; 0.47 mg/L vs. 0.67 mg/L, respectively, for the Namwon Study). This association was not attenuated after adjustment for age, sex, BMI, smoking, diabetes and hypertension, total cholesterol, HDL cholesterol, and log-transformed triglycerides (0.50 mg/L vs. 0.67 mg/L; 0.37 mg/L vs. 0.67 mg/L, respectively, for the Dong-gu Study and 0.47 mg/L vs. 0.66 mg/L; 0.45 mg/L vs. 0.66 mg/L, respectively, for the Namwon Study).

Carriers of *E4* allele had significantly lower CRP levels compared with carriers of *APOE E3* allele in both studies (0.50 mg/L vs. 0.67 mg/L for the Dong-gu Study and 0.48 mg/L vs. 0.67 mg/L for the Namwon Study). This association was not attenuated after adjustment for potential confounders (0.49 mg/L vs. 0.67 mg/L for the Dong-gu Study and 0.47 mg/L vs. 0.66 mg/L for the Namwon Study). There was no difference in CRP levels between carriers of *E2* allele and carriers of *E3* alleles.

The variance of CRP explained by the *APOE* genotype after adjustment for covariates was 1.6% in both studies. However, there was no difference in WBC among *APOE* genotypes in both studies ([Table 3](#T3){ref-type="table"}).

DISCUSSION
==========

In this population based study, we observed that the *E3E4* and *E4E4* genotypes were associated with lower C-reactive protein compared with the *E3E3* genotype group, while WBC count was not associated with *APOE* genotype. To our knowledge, this is the largest population-based study on the association of the *APOE* genotype and CRP levels and WBC count.

Our results that *E3E4* and *E4E4* genotype are associated with lower CRP levels are in agreement with previous studies ([@B17], [@B18], [@B19], [@B20], [@B21], [@B22], [@B23], [@B24], [@B25], [@B26]). In a few studies, there was no association between *APOE E4* allele and low CRP levels ([@B30], [@B31]). The small sample size of these studies might have contributed to the negative findings. Recently, Hubacek et al. ([@B25]) observed the lowest CRP levels in carriers of the *APOE E3E4* and *E4E4* genotypes in a large general population sample of 6,230 aged 45-69 yr. In a meta-analysis in Asians including a Korean cohort and two Filipino cohorts, *APOE E4* haplotype was significantly associated with decreased CRP levels compared to the *APOE E3* haplotype ([@B32]).

There is still limited research on the association of *APOE* genotype with pro- and anti-inflammatory markers except for CRP in humans. In the present study, *APOE* genotype was not associated with WBC count. There was only one study that reported an association between *APOE* genotype and WBC count ([@B18]), which is in accordance with our study. This study showed that the *APOE* genotype is associated with CRP levels, but not white blood cells. However, a limitation of this study is the small sample number of participants who had undergone coronary angiography. Tziakas et al. ([@B33]) reported that *E3E4* carriers were not only associated with lower levels of IL-10, an anti-inflammatory cytokine, but also with lower CRP levels, an inflammatory marker in patients with acute coronary syndrome and chronic stable angina. Tziakas et al. ([@B33]) speculated that in E4 carriers, the deleterious effects of low IL-10 levels may outweigh the protective effects of low CRP levels found in these patients, and that an imbalance between anti- and pro-inflammatory forces may be responsible for the increased CAD risk associated with the *E4* allele. Drabe et al. ([@B34]) reported that the presence of the *E4* allele is associated with increased release of IL-8 and TNF-alpha in 22 patients receiving standard coronary artery bypass grafting. Further studies are needed to clarify the association of *APOE* genotype and inflammation markers.

The underlying mechanisms by which *APOE* genotype affects CRP levels are poorly understood. This mechanism may not be related to inflammation for following reasons. First, the negative association between *E4* allele and CRP levels is in contradiction to the observation that *E4* allele is a risk factor for CVD and Alzheimer\'s disease ([@B13], [@B35]) and has been associated with increased brain and macrophage inflammation ([@B36]). Second, in our study, there was no association between *APOE* genotype and WBC count, an important cellular marker of systemic inflammation. März et al. ([@B18]) postulated that the metabolism of CRP could be related to the activity of the mevalonate pathway in the liver, since in *E4* carriers, the mevalonate pathway that produces cholesterol in vivo is downregulated, which could also lead to low production of CRP. This postulation can be supported by the findings that statins, the inhibitor of the mevalonate pathway, cannot only reduce the cholesterol biosynthesis but also CRP levels ([@B18], [@B37]). However, this hypothesis has not been verified and the possible biological mechanisms are not entirely clear. It may be necessary to see whether the *APOE* genotype would modify the association between CRP and inflammation-related disease. Because of the two opposing effects of *APOE E4* on inflammation, *APOE E4* allele may influence atherosclerosis in a positive or negative way and using CRP as the biomarker in assessing CVD risk could underestimate the CVD risk in the carriers of *E4* allele ([@B36]).

The strengths of this study are its very large sample size and adequate statistical power to assess whether *APOE* genotype is associated with CRP levels. Our study has some limitations. First, we measured the CRP levels and WBC count only once in this study, which may have affected the results. However, the within-person biologic variation of CRP is low ([@B38]) and so there may be little bias. Second, we did not measure other inflammatory markers such as interleukin-6, tumor necrosis factor-α, and fibrinogen which might have helped us to better clarify the relationship between *APOE* genotype and inflammation.

In conclusion, our data demonstrated that the *APOE E4* allele is associated with lower CRP levels, but not WBC count. Our results suggest that *APOE* genotype may influence CRP levels through a non-inflammatory pathway.
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###### Baseline characteristics of the study subjects

![](jkms-30-860-i001)

  Parameters                             Dong-gu study (n = 8,893)   Namwon study (n = 10,032)   *P* value
  -------------------------------------- --------------------------- --------------------------- -----------
  Age (yr)                               65.1 ± 8.2                  61.6 ± 8.0                  \< 0.001
  Men (%)                                3,525 (39.6)                3,909 (39.0)                0.344
  Body mass index (kg/m^2^)              24.4 ± 2.9                  24.4 ± 3.1                  0.617
  Current smoking (%)                    962 (10.8)                  1,512 (15.1)                \< 0.001
  Hypertension (%)                       3,960 (44.5)                3,945 (39.3)                \< 0.001
  Diabetes mellitus (%)                  1,662 (18.7)                1,205 (12.0)                \< 0.001
  Total cholesterol (mg/dL)              201.3 ± 39.9                189.3 ± 37.0                \< 0.001
  HDL cholesterol (mg/dL)                51.6 ± 11.9                 47.6 ± 12.0                 \< 0.001
  Triglycerides (mg/dL)^\*^              118.0 (84.0-172.0)          130.0 (89.0-193.0)          \< 0.001
  C-reactive protein (mg/L)^\*^          0.60 (0.30-1.20)            0.60 (0.30-1.30)            0.104
  White cell blood count ( × 10^3^/µL)   5.81 ± 1.53                 6.20 ± 1.60                 \< 0.001
  Myocardial infarction (%)              114 (1.3)                   37 (0.4)                    \< 0.001
  Stroke (%)                             369 (4.1)                   352 (3.5)                   0.022

Data are means±SD, medians (interquartile range)^\*^ or n (%). HDL, high density lipoprotein.

###### Adjusted geometric means and 95% confidence intervals for C-reactive protein (mg/L) in different *APOE* genotypes or alleles
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  Genotypes   Dong-gu study   Namwon study                                                                         
  ----------- --------------- ----------------------- ---------------------- -------------- ---------------------- ----------------------
  *E2E2*      40 (0.4)        0.57 (0.43-0.77)        0.61 (0.46-0.81)       40 (0.4)       0.62 (0.44-0.87)       0.67 (0.48-0.93)
  *E2E3*      954 (10.7)      0.66 (0.62-0.70)        0.68 (0.64-0.72)       1,026 (10.2)   0.67 (0.63-0.72)       0.71 (0.66-0.76)
  *E2E4*      115 (1.3)       0.52 (0.44-0.62)        0.53 (0.45-0.63)       106 (1.1)      0.62 (0.51-0.77)       0.65 (0.53-0.79)
  *E3E3*      6,312 (71.0)    0.67 (0.65-0.68)        0.67 (0.65-0.68)       7,280 (72.6)   0.67 (0.65-0.68)       0.66 (0.65-0.68)
  *E3E4*      1,386 (15.6)    0.51 (0.49-0.54)^†^     0.50 (0.48-0.53)^†^    1,493 (14.9)   0.48 (0.45-0.51)^†^    0.47 (0.44-0.49)^†^
  *E4E4*      86 (1.0)        0.37 (0.31-0.46)^†^     0.37 (0.30-0.45)^†^    87 (0.9)       0.47 (0.37-0.59)^†^    0.45 (0.36-0.57)^†^
                              *P* \< 0.001            *P* \< 0.001                          *P* \< 0.001           *P* \< 0.001
                              Partial R^2‡^ = 0.014   Partial R^2^ = 0.016                  Partial R^2^ = 0.012   Partial R^2^ = 0.016
  *E2*        994 (11.2)      0.66 (0.62-0.70)        0.68 (0.64-0.72)       1,066 (10.6)   0.67 (0.63-0.72)       0.71 (0.66-0.75)
  *E3*        6,312 (71.0)    0.67 (0.65-0.68)        0.67 (0.65-0.68)       7,280 (72.6)   0.67 (0.65-0.68)       0.66 (0.65-0.68)
  *E4*        1,472 (16.6)    0.50 (0.48-0.53)^†^     0.49 (0.47-0.52)^†^    1,580 (15.7)   0.48 (0.45-0.51)^†^    0.47 (0.44-0.49)^†^
                              *P* \< 0.001            *P* \< 0.001                          *P* \< 0.001           *P* \< 0.001
                              Partial R^2^ = 0.012    Partial R^2^ = 0.015                  Partial R^2^ = 0.012   Partial R^2^ = 0.016

Values are geometric mean (95% confidence interval). ^\*^Adjusted for age, sex, BMI, smoking, hypertension, diabetes mellitus, total cholesterol, HDL cholesterol, and log triglycerides. ^†^*P*\<0.05 compared with *E3/E3* or *E3* with a Bonferroni multiple comparisons test; ^‡^Variance explained by *APOE* genotype after adjustment for covariates.

###### Adjusted means and 95% confidence intervals for white blood cell count in different *APOE* genotypes or alleles
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  Genotypes   Dong-gu study   Namwon study                                                            
  ----------- --------------- ------------------ ------------------ -------------- ------------------ ------------------
  *E2E2*      40 (0.4)        5.60 (5.13-6.07)   5.56 (5.11-6.01)   40 (0.4)       5.70 (5.21-6.20)   5.82 (5.35-6.28)
  *E2E3*      954 (10.7)      5.82 (5.72-5.92)   5.83 (5.73-5.92)   1,026 (10.2)   6.21 (6.11-6.31)   6.22 (6.12-6.31)
  *E2E4*      115 (1.3)       5.72 (5.44-6.00)   5.72 (5.46-5.99)   106 (1.1)      6.04 (5.73-6.34)   6.07 (5.79-6.36)
  *E3E3*      6,312 (71.0)    5.80 (5.76-5.84)   5.80 (5.77-5.84)   7,280 (72.6)   6.20 (6.17-6.24)   6.20 (6.17-6.24)
  *E3E4*      1,386 (15.6)    5.88 (5.80-5.96)   5.87 (5.79-5.94)   1,493 (14.9)   6.16 (6.08-6.25)   6.16 (6.08-6.23)
  *E4E4*      86 (1.0)        5.75 (5.43-6.07)   5.73 (5.42-6.03)   87 (0.9)       6.18 (5.84-6.51)   6.11 (5.8-6.43)
                              *P* = 0.412        *P* = 0.512                       *P* = 0.328        *P* = 0.414
  *E2*        994 (11.2)      5.81 (5.72-5.91)   5.82 (5.73-5.91)   1,066 (10.6)   6.19 (6.1-6.29)    6.20 (6.11-6.29)
  *E3*        6,312 (71.0)    5.80 (5.76-5.84)   5.80 (5.77-5.84)   7,280 (72.6)   6.20 (6.17-6.24)   6.21 (6.17-6.24)
  *E4*        1,472 (16.6)    5.88 (5.80-5.95)   5.86 (5.78-5.93)   1,580 (15.7)   6.16 (6.09-6.24)   6.16 (6.08-6.23)
                              *P* = 0.204        *P* = 0.415                       *P* = 0.667        *P* = 0.493

Values are arithmetic mean (95% confidence interval) for white blood cell count (×10^3^/µL). ^\*^Adjusted for age, sex, BMI, smoking, hypertension, diabetes mellitus, total cholesterol, HDL cholesterol, and log triglycerides.
